Home » Stocks » AGIO

Agios Pharmaceuticals, Inc. (AGIO)

Stock Price: $44.70 USD -0.55 (-1.22%)
Updated December 4, 4:00 PM EST - Market closed

AGIO Stock Price Chart

Key Info

Market Cap 3.10B
Revenue (ttm) 194.59M
Net Income (ttm) -332.06M
Shares Out 69.14M
EPS (ttm) -4.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $44.70
Previous Close $45.25
Change ($) -0.55
Change (%) -1.22%
Day's Open 45.56
Day's Range 44.30 - 46.16
Day's Volume 424,750
52-Week Range 31.52 - 55.93

AGIO Stock News

Zacks Investment Research - 3 days ago

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

GlobeNewsWire - 5 days ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...

Zacks Investment Research - 3 weeks ago

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.

GlobeNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...

Zacks Investment Research - 4 weeks ago

Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.

Seeking Alpha - 4 weeks ago

Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript

Benzinga - 1 month ago

  Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.

GlobeNewsWire - 1 month ago

– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –

GlobeNewsWire - 1 month ago

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...

Zacks Investment Research - 1 month ago

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...

Seeking Alpha - 1 month ago

Agios: A Look At Mitapivat In Anaemia, Its Backup Indication

Zacks Investment Research - 1 month ago

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.

Seeking Alpha - 1 month ago

Agios: A Look At TIBSOVO In CC Patients

GlobeNewsWire - 1 month ago

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –

Zacks Investment Research - 2 months ago

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 2 months ago

– Supplemental New Drug Application Planned f or Submission in Q1 2021 –

GlobeNewsWire - 2 months ago

Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020  

Seeking Alpha - 3 months ago

Tibsovo sales, after weakness during launch, are ramping nicely.

Zacks Investment Research - 3 months ago

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...

Seeking Alpha - 4 months ago

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 4 months ago

– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –

Zacks Investment Research - 4 months ago

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ...

Zacks Investment Research - 5 months ago

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...

GlobeNewsWire - 5 months ago

– Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments –

GlobeNewsWire - 5 months ago

– 5 of 8 (63%) Efficacy Evaluable Patients Achieved a Hemoglobin Increase of ≥1.0 g/dL From Baseline –

GlobeNewsWire - 5 months ago

– Treatment with Mitapivat Induced Hemoglobin (Hb) Increase of ≥1.0 g/dL in 12 of 13 (92%) Evaluable Patients, Including 4 of 4 (100%) α-Thalassemia Patients, During Weeks 4-12 –

Zacks Investment Research - 5 months ago

Is (AGIO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 5 months ago

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ...

The Motley Fool - 5 months ago

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: JNCE, MRSN, STRO
Zacks Investment Research - 6 months ago

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 6 months ago

– Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months –

Zacks Investment Research - 6 months ago

Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 6 months ago

Is (AGIO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 6 months ago

– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma –

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals

Investors Business Daily - 6 months ago

Agios Pharmaceuticals sees its Relative Strength Rating reach the 80-plus level. The post Stocks To Watch: Agios Pharmaceuticals Sees RS Rating Jump To 85 appeared first on Investor's Business...

Zacks Investment Research - 6 months ago

Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.

Seeking Alpha - 7 months ago

Agios Pharmaceuticals, Inc.'s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

About AGIO

Agios Pharmaceuticals, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutatio... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2013
CEO
Jacqualyn Fouse
Employees
536
Stock Exchange
NASDAQ
Ticker Symbol
AGIO
Full Company Profile

Financial Performance

In 2019, AGIO's revenue was $117.91 million, an increase of 24.92% compared to the previous year's $94.39 million. Losses were -$411.47 million, 18.9% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for AGIO is 63.83, which is an increase of 42.80% from the latest price.

Price Target
$63.83
(42.80% upside)